|
Lupus Erythematosus, Systemic
|
0.550 |
GeneticVariation
|
disease |
BEFREE |
Therefore, the binding of KLF4 and the subsequent recruitment of HDACs represent a mechanism for reduced BLIMP1 expression in MO-DCs bearing the SLE risk allele rs548234.
|
28097234 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.550 |
AlteredExpression
|
disease |
BEFREE |
The increased mRNA expression of Blimp1 seemed to be related to SLE disease activity and anti-nuclear antibody (ANA) titer.
|
23911415 |
2013 |
|
Lupus Erythematosus, Systemic
|
0.550 |
GeneticVariation
|
disease |
BEFREE |
Given that the murine lupus susceptibility locus Nba2 includes the IFN-regulated genes Ifi202 (encoding for the p202 protein), Aim2 (encoding for the Aim2 protein), and Fcgr2b (encoding for the FcγRIIB receptor), we investigated whether the IRF5/Blimp-1 axis could regulate the expression of these genes.
|
22116829 |
2012 |
|
Lupus Erythematosus, Systemic
|
0.550 |
GeneticVariation
|
disease |
BEFREE |
Genetic association of PRDM1-ATG5 intergenic region and autophagy with systemic lupus erythematosus in a Chinese population.
|
21622776 |
2011 |
|
Lupus Erythematosus, Systemic
|
0.550 |
GeneticVariation
|
disease |
BEFREE |
This replication effort identified five new SLE susceptibility loci (P < 5 x 10(-8)): TNIP1 (odds ratio (OR) = 1.27), PRDM1 (OR = 1.20), JAZF1 (OR = 1.20), UHRF1BP1 (OR = 1.17) and IL10 (OR = 1.19).
|
19838195 |
2009 |
|
Lupus Erythematosus, Systemic
|
0.550 |
Biomarker
|
disease |
CTD_human |
This replication effort identified five new SLE susceptibility loci (P < 5 x 10(-8)): TNIP1 (odds ratio (OR) = 1.27), PRDM1 (OR = 1.20), JAZF1 (OR = 1.20), UHRF1BP1 (OR = 1.17) and IL10 (OR = 1.19).
|
19838195 |
2009 |
|
Lupus Erythematosus, Systemic
|
0.550 |
Biomarker
|
disease |
MGD |
|
|
|
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
BLIMP-1 expression was frequently associated with the ABC phenotype and plasmablastic morphologic subtype of DLBCL, yet 63% of the ABC-DLBCL patients were negative for BLIMP-1 protein expression.
|
27568520 |
2017 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The tumor suppressors B-lymphocyte-induced maturation protein-1 (BLIMP-1) and p53 play a crucial role in B-cell lymphomas, and their inactivation contributes to the pathogenesis of a wide spectrum of lymphoid malignancies, including diffuse large B-cell lymphomas (DLBCLs).
|
28474779 |
2017 |
|
Ulcerative Colitis
|
0.400 |
GeneticVariation
|
disease |
GWASCAT |
Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci.
|
26974007 |
2016 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Discordance of PRDM1 messenger RNA and protein expressions is associated with high EBV-miR-BHRF1-2 levels in LCLs and primary post-transplant EBV-positive DLBCL.
|
26530011 |
2016 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
BLIMP1 is frequently inactivated in a variety of lymphomas, including diffuse large B cell lymphomas, Natural Killer cell lymphoma and anaplastic large T cell lymphoma.
|
25115512 |
2015 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PRDM1/Blimp-1 is a tumor suppressor gene in the activated B-cell subtype of diffuse large B-cell lymphomas.
|
25382611 |
2014 |
|
Ulcerative Colitis
|
0.400 |
GeneticVariation
|
disease |
GWASCAT |
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47.
|
21297633 |
2011 |
|
Ulcerative Colitis
|
0.400 |
GeneticVariation
|
disease |
GWASDB |
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47.
|
21297633 |
2011 |
|
Ulcerative Colitis
|
0.400 |
Biomarker
|
disease |
CTD_human |
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47.
|
21297633 |
2011 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PRDM1/Blimp1 is a master regulator of terminal B cell differentiation and may also function as a tumor suppressor in the pathogenesis of DLBCL, where it is frequently inactivated by mutations and deletions.
|
21722313 |
2011 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, abnormal epigenetic down-regulation of PRDM1 by let-7 and other microRNAs may represent an alternative mechanism of reducing normal PRDM1 function in a subset of DLBCL with relatively high PRDM1alpha mRNA expression and unmutated PRDM1.
|
20651244 |
2010 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Recently, mutational inactivation of Blimp-1 has been identified in a subset of diffuse large B-cell lymphomas of the activated B-cell type.
|
20047096 |
2010 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together with previous reports, the present results suggest that two key transcription factors for the plasmacytic differentiation, XBP1 and BLIMP1, are involved in the pathogenesis in diffuse large B-cell lymphoma.
|
19380033 |
2009 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PRDM1/Blimp-1, a master regulator in terminal B-cell differentiation, has been recently identified as a tumor suppressor target for mutational inactivation in diffuse large B-cell lymphomas of the activated B-cell type.
|
18583325 |
2008 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The PRDM1 gene was found homozygously deleted in a case of DLBCL.
|
18297524 |
2008 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently, new roles for Blimp-1 have been revealed, as a suppressor of diffuse large B cell lymphoma and as a key regulator of T-cell differentiation.
|
17291741 |
2007 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PRDM1 protein expression was recently demonstrated in a subset of diffuse large B-cell lymphoma (DLBCL) with aggressive behavior, a type of lymphoma for which rituximab associated with chemotherapy (R-CHOP) is now widely indicated.
|
17379744 |
2007 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Here, we describe novel mutations in the BLIMP1 gene in 2 of 15 (13%) cases of B-cell lymphoma (two cases of primary effusion lymphoma and 13 cases of diffuse large B-cell lymphoma).
|
17213024 |
2007 |